Work Here?
Prolific Machines
Work Here?
Develops cost-efficient cultured meat production
Prolific Machines
Work Here?
Develops cost-efficient cultured meat production
Overview
temp
About Prolific Machines
Industries
Food & Agriculture
Industrial & Manufacturing
Biotechnology
Company Size
51-200
Company Stage
Series B
Total Funding
$97M
Headquarters
Emeryville, California
Founded
2020
Get referred to Prolific Machines
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 2026 Gates Foundation grant funds affordable monoclonal antibodies for low-income countries.
- 2026 site lists services for biotechs, CDMOs, and licensing, broadening revenue paths.
- May 2025 FDA program status improves credibility with regulators and pharma partners.
What critics are saying
- The company pivoted from cultured meat toward biopharma, confusing employer branding and hiring.
- No 2026 customer revenues are public, so commercialization still depends on partner conversions.
- If biomanufacturing deals stall, Prolific risks becoming a funded platform without durable demand.
What makes Prolific Machines unique
- 2026 website says Prolific integrates optogenetic cell lines, illumination, AI optimization.
- May 2025 FDA Emerging Technology Program entry validates its industrial biomanufacturing platform.
- June 2024 Series B1 drew Fonterra, Breakthrough Energy Ventures, and In-Q-Tel.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$97M
Above
Industry Average
Funded Over
3 Rounds
Industry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Hybrid Work Options
Company Equity
Mental Health Support
Paid Vacation
Meal Benefits
Company Social Events
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↓ -2%2 year growth
↑ 0%Christina Perry, MSA, CPA, former Chief Financial Officer (CFO) of Forge Biologics, recently acquired by Ajinomoto Co., has been appointed as CFO of Prolific Machines to support the company's meteoric growth as it works towards building a resilient, sustainable business.
Prolific Machines receives Bill & Melinda Gates Foundation grant to leverage optogenetics expertise to develop more affordable monoclonal antibodies.
Biotechnology startup Prolific Machines, which uses a photomolecular platform to create new proteins at low costs, has raised $55 million in a Series B1 round led by Fonterra's VC arm, The Ki Tua Fund. Other investors include Breakthrough Energy Ventures, Mayfield, SOSV, Shorewind Capital, Darco Capital, Conti Ventures, and In-Q-Tel (IQT). The funding will be used to commercialize their platform through industry partnerships.
Prolific Machines harnesses light-sensitive proteins to control cells used in biomanufacturing using optogenetics.
Prolific Machines announced on Thursday that it raised $55 million in a Series B round led by the Ki Tua Fund, the corporate venture capital division of New Zealand-based dairy giant Fonterra Co-operative Group.
Prolific Machines is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Prolific Machines
Industries
Food & Agriculture
Industrial & Manufacturing
Biotechnology
Company Size
51-200
Company Stage
Series B
Total Funding
$97M
Headquarters
Emeryville, California
Founded
2020
Prolific Machines is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today